Regulatory Submission Translation Services

Regulatory submission translation for markets that read in different languages

A regulatory dossier is a legal argument backed by evidence, and the evidence rarely arrives in one language. German bench test reports, Japanese clinical literature, Italian manufacturing records, French biocompatibility studies: sooner or later, all of it has to be presented to an authority that reads something else. Regulatory submission translation is the discipline of moving that evidence between languages without weakening the argument, and it is work we have been doing for medical device, pharmaceutical, and chemical manufacturers for fifteen years.

The stakes are asymmetrical. A marketing text translated poorly embarrasses you; a submission translated poorly stops the review. Authorities do not interpret charitably. A test report whose translated conclusion is a shade softer than the original invites a deficiency letter, and every deficiency letter costs weeks. So the operating principle across everything on this page is fidelity you can defend: what the source document claims, no more and no less, in the register the reviewing authority expects.

We translate premarket submissions and their exhibits, technical documentation for CE marking, registration dossiers for chemicals, and the correspondence that follows a filing. For sister document types, from safety data sheets to conformity paperwork, our full coverage is listed on this page.

Filing with FDA when your evidence was not written in English

FDA works in English. When a 510(k) or PMA relies on documents originally produced in another language, the agency expects a complete English translation accompanied by the original and a statement attesting to the translation's accuracy. This surfaces at the worst possible moment for unprepared teams: the Refuse to Accept screening, where an administrative gap can bounce a submission before any scientific review begins.

A typical case from our files: a German surgical instrument manufacturer preparing a 510(k) through a US regulatory consultant. The performance data lived in eleven German test reports from two accredited labs, plus a sterilization validation written in dense laboratory German. We delivered certified English translations of all thirteen documents in ten business days, each with a signed certificate of accuracy naming the translator and credentials, formatted so the consultant could drop them directly into the submission. The 510(k) passed RTA screening on the first attempt. Much of this work reaches us through the medical device industry, and German sources are frequent enough that we keep dedicated reviewers on our German technical translation bench.

Two habits make FDA work smoother. First, translate the lab reports completely, including the boilerplate accreditation statements, because reviewers notice omissions faster than errors. Second, keep source terminology aligned with the predicate device literature already on file, so the comparison the submission is built on reads cleanly. Where a foreign report references standards by their national designations, we retain the original designation and add the recognized equivalent in brackets only when the client's regulatory consultant confirms it, because an assumed equivalence is a claim the submission then has to defend.

Selling a device in Europe: MDR 2017/745 makes language a market requirement

The EU Medical Device Regulation turned language from an afterthought into a gating requirement. Under MDR 2017/745, the information supplied with the device, meaning the IFU, labeling, and safety information, must be provided in the official language or languages determined by each member state where the device is made available. Some states accept English for professional-use devices; most require their national language for anything reaching patients or lay users. A manufacturer covering the major EU markets routinely needs 15 or more language versions, all consistent with the technical documentation behind them.

That last clause is where programs fail. The IFU claims are bound to the clinical evaluation, the risk management file, and the declaration of conformity translation that accompanies the device. If the Spanish IFU drifts from the English master, the notified body can and does raise it. Our workflow treats English as the single controlled source: every language version is generated from the same source revision, tagged with it, and updated together when the master changes. Nothing is translated from a translation.

Symbols and residual text need equal attention. ISO 15223-1 symbols reduce the translated word count on labels, but the words that remain, storage conditions, warnings, intended purpose statements, carry the regulatory weight. And because eIFU rules let some professional-use devices move instructions online, the language matrix has to distinguish what ships in the box from what lives on the server, market by market. We map that matrix with you once, then maintain it release after release.

Inside the dossier: technical files, eCTD, and where translation fits

Different products, different skeletons. Devices follow MDR Annex II and III technical documentation; drugs follow the eCTD structure. Knowing the skeleton tells the translator what each document is for, which changes how it should read.

Dossier element	Authority	Language reality
510(k) / PMA and exhibits	FDA	English, with certified translations of foreign-language evidence
MDR technical documentation (Annex II/III)	Notified body	Usually English accepted; confirm with your notified body
IFU, labeling, safety information	EU member states	National languages as each state requires
eCTD Modules 1–5	FDA / EMA / national agencies	Module 1 is regional; foreign study reports translated for the reviewing agency
REACH / chemical registrations	ECHA / national helpdesks	Study summaries and exposure scenarios per agency language rules

In eCTD work, granularity is the translator's friend: documents live as discrete leaf files, so translations can be produced, versioned, and replaced one leaf at a time without disturbing the rest of the sequence. We deliver files named and structured to your publishing tool's conventions, ready for your regulatory operations team to place. Chemical registration work follows the same logic, and it connects naturally to the chemical sector dossiers we support, where study summaries and exposure scenarios cross between English, German, and French constantly.

Translation quality is approval speed

Regulatory timelines are mostly waiting, punctuated by short windows where everything is urgent. A deficiency letter or additional information request typically allows a fixed response period, and if part of your response is a foreign-language study that now needs translating, the translation sits directly on the critical path. We hold rush capacity for exactly this, and we have turned certified translations of individual test reports in 24 to 48 hours when a response deadline demanded it.

Quality here has a specific shape. Terminology must match the controlled vocabularies of the domain: MedDRA for adverse events, ISO 10993 terms for biocompatibility, pharmacopoeial names for excipients. Claims language must stay inside what the source supports; "demonstrates" cannot become "suggests" or the reverse. And documents that cite harmonized standards must cite them exactly, a discipline we share with our work on SDS translation services, where codified phrases leave the translator no creative license at all.

Traceability: the part auditors ask about

Submissions get audited, sometimes years later. Each project therefore leaves a trail: which translator, which reviser, which source revision, which glossary version, which date. Certificates of accuracy identify the linguists and their credentials. Bilingual review tables let your regulatory team verify any passage against its source in seconds. Our process follows ISO 17100, with independent revision by a second qualified specialist on every document, and as an ATA and GALA member agency we can evidence translator qualifications when an auditor or authority asks.

The same traceability covers validation documents that support submissions. When an imported production line arrives with qualification protocols in Italian or German, we translate them so your quality team can execute and reference them in the dossier; our team also translates IQ, OQ, and PQ validation protocols as a companion service, with acceptance criteria checked line by line against the source.

Beyond FDA and Brussels: the other desks your dossier will visit

Companies rarely stop at two markets. Health Canada expects device labeling in English and French, and the French must satisfy Quebec's language expectations, not merely gesture at them. Japan's PMDA reviews in Japanese, and the quality of the Japanese application materials shapes the consultation meetings that precede filing. China's NMPA requires Chinese documentation prepared to its own templates, where a translation that reads like a translation slows everything down. Brazil's ANVISA works in Portuguese, with its own vocabulary for device classes and registration routes that does not map one-to-one onto FDA's.

Multi-market programs succeed on sequencing. The English master dossier is stabilized first; market-specific versions are then generated in parallel by translators who work into their native language and know the receiving agency's conventions. Local regulatory consultants review our drafts where the client engages them, and their comments come back through one terminology layer so the Japanese and Portuguese versions do not quietly diverge on substance. The submission dates may be months apart, but the evidence they present must remain the same evidence.

Put translation on the project plan, not on the critical path

Most regulatory translation emergencies were foreseeable at kickoff. The test reports existed in German before anyone booked the filing date; the IFU languages were determined the day the market list was agreed. A half-hour scoping conversation at project start, listing every foreign-language document and every required target language, converts almost all of this from emergency to routine.

We help regulatory teams build that inventory. The output is a simple translation schedule aligned to the filing calendar: which documents, which languages, which certification format, which dates, and what buffer remains for the response windows that follow submission. Budget behaves better too, since planned work is priced as planned work, and the rush premium is reserved for genuine surprises. Teams that run this exercise once tend to repeat it on every subsequent filing, which is how most of our long-term regulatory relationships started.

The dossier lives on after approval

Approval is not the end of the language problem. Devices and drugs live under change control: design changes trigger documentation updates, which trigger IFU revisions, which trigger re-translation into every market language, on a deadline, with each version's history intact. Post-market surveillance adds incident reports and field safety corrective actions that must move between languages quickly, because vigilance reporting windows are counted in days.

We manage this as a standing service rather than a series of one-off projects. Your translation memory, termbase, and version map persist with us, so an updated IFU costs a fraction of the original translation and arrives consistent with it. When notified bodies or agencies update their expectations, as happens regularly with guidance documents and harmonized standards lists, the terminology layer is updated once and applied everywhere. Standards themselves sometimes need translating along the way; learn more here about how we handle those, including the copyright questions they raise.